Back to Search Results
Study Complete
Sponsor ID
20030204

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects with Anemia of Cancer

Sponsor ID
20030204
Clinicaltrials.gov ID
NCT00095277
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

The purpose of this trial is to demonstrate benefit with respect to hematopoietic response in subjects with anemia of cancer randomized to Darbepoetin Alfa once every 4 weeks.

Additional Study Details

Phase
Phase 2
Product
darbepoetin alfa
Type
Interventional
Masking
N/A
Enrollment
220
Additional Study Details

Protocol Summary

Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available

Study Documents

Study Synopsis
Available Language(s): English
Download Document(s)

Locations

No locations found.
Study Info
Age
18+ years
Condition
  • Anemia
    • Sex
    All
    Trial Dates
    Jun 2004 - N/A
    Inclusion and Exclusion Criteria
    Eligibility Criteria: - Subjects with non-myeloid malignancies - Subjects can not be on chemotherapy - Anemia of cancer - Eastern Cooperative Oncology Group (ECOG) status of 0 to 2 - Hemoglobin less than or equal to 11.0 g/dL - Adequate renal and liver function - Written informed consent